Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

KYOWA HAKKO KIRIN CO LTD

(4151)
My previous session
Most popular
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Kyowa Hakko Kirin : signs drug discovery deal with AI firm InveniAI

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 04:49am EDT

Japanese pharma and biotech firm Kyowa Hakko Kirin is joining the growing trend of investing in artificial intelligence to bolster drug discovery efforts, entering a new partnership with AI and machine learning firm InveniAI.

KHK hopes to utilise InveniAIs AlphaMeld technology to discover how its existing pipeline products can be applied to other indications.

While the exact financial details of the deal were not disclosed, it was confirmed that an upfront sum will be paid to InveniAI, as well as a number of development and commercialisation payments.

As we seek to fulfil our business vision to bring innovative treatments to patients faster, we very much expect that InveniAIs platform, will not only enable us to identify alternate therapeutic value for our portfolio at an unprecedented speed, but also capitalize on our existing investment by reducing the time to market, clinical cost of development and enhancing the probability of clinical success, commented Dr Mitsuo Satoh, KHKs Executive Officer, Vice President, Head, R&D Division.

Dr Krishnan Nandabalan, CEO and President of InveniAI, also remarked on the deal: We are extremely pleased to initiate this collaboration to build on Kyowa Hakko Kirins clinically rich pipeline. AlphaMeld has industrialised the process of drug re-innovation by enabling the identification of complex associations between drugs/mechanisms and disease indications. The platform is patient-validated where multiple drug concepts have progressed through to human proof of clinical development.

The company follows in the steps of a number of other industry players to sign similar AI drug discovery deals, including Novo Nordisk and UK-based e-Therapeutics, and Pfizer and CytoReason.

(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
KIRIN HOLDINGS CO LTD -2.69% 2554 End-of-day quote.13.33%
KYOWA HAKKO KIRIN CO LTD -1.81% 2279 End-of-day quote.12.43%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on KYOWA HAKKO KIRIN CO LTD
03/25KYOWA HAKKO KIRIN : Enters New Development and Commercialisation Agreements with..
PU
03/18KYOWA HAKKO KIRIN : Kirin Asia Pacific Announces Establishment of Subsidiary in ..
BU
03/04KYOWA HAKKO KIRIN : Kirin Announces Refiling of Istradefylline (KW-6002)'s New D..
AQ
02/16Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita (bu..
AQ
02/15Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita fro..
AQ
02/09Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a P..
AQ
02/07Kyowa Hakko Kirin Initiated Phase 2 Clinical Study of Tenapanor for Hyperphos..
AQ
02/06KYOWA HAKKO KIRIN : Announces Organizational Changes
AQ
02/06KYOWA HAKKO KIRIN : Offer of Voluntary Early Retirement
AQ
02/06KYOWA HAKKO KIRIN : Announces Changes in the Executive Directors
AQ
More news
Financials (JPY)
Sales 2019 310 B
EBIT 2019 -
Net income 2019 59 271 M
Finance 2019 72 547 M
Yield 2019 1,73%
P/E ratio 2019 20,77
P/E ratio 2020 25,81
EV / Sales 2019 3,74x
EV / Sales 2020 3,43x
Capitalization 1 231 B
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KYOWA HAKKO KIRIN CO LTD
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 710  JPY
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Nobuo Hanai Chairman & Chief Executive Officer
Masashi Miyamoto President, COO & Representative Director
Mitsuo Satoh Executive Officer, GM-Research & Development
Toshifumi Mikayama Director & Senior Managing Executive Officer
Yoshiko Leibowitz Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO LTD12.43%11 176
ABBVIE-13.75%117 653
WUXI APPTEC CO LTD25.10%16 546
MERCK KGAA9.69%14 412
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD24.42%9 774
JAZZ PHARMACEUTICALS PLC10.46%7 794